Type of the current chemotherapy drugs and cancer [believed according to the comprehensive studies previously conducted Compendia Bioscience in effective treatments, may be certification.
One may use extensions (identified by the research team) medicine is the Heceptin. Has been approved as a treatment which effective long breast cancer tumor Herceptin to showcase the human epidermal growth factor receptor 2 (HER2) result in personal. This genetic mutations and diseases in traditional medicine treatment becomes difficult.
In recent years, as a viable option for the treatment of patients with FDA stomach expand Herceptin use same HER2 consequence exhibition gostroephogeal cancer.
Can you provide a wider use of other well known drug contains gefitinib (Iressa) and erlotinib (Tarceva).
Rather specific gene mutations in the target and then body for these drugs are effective. 4, 118 Identified cancer to showcase Compendia life the same mutation from patients taking cancer tumor genetic makeup analysis by the number.
22 For the research team to treat existing currently targeting genes looked specifically. 438 Will benefit from the existing treatments among all patients like to recommend genetic exhibited the expansion of the DNA was enough. This is the current of the brain, breast, colon, lung, ovarian, pancreatic cancer cancer shows the patient's 5-10% effectively currently on the market with drugs to treat.
Looking for expanded utilization of drugs Herceptin effectiveness in gastric tumor in initial victory as eligible for the problem to the function. FDA approval for expanded utilization, "Trastuzumab stomach is a cancer published in August 2010, and then complete the" trial comes to the Lord.
In the trial, gastric cancer patients is the consequence of HER2 and decreased mortality 26 %trastuzumab and certain combinations in conventional chemotherapy compared chemotherapy alone were not found.
Compendia Bioscience research findings was reported at the Berlin Conference of cancer treatment are hosted on the organisation of European research and cancer, National Cancer Institute and American Association.
No comments:
Post a Comment